Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France)

被引:23
作者
Breton, J
Sichel, F
Abbas, A
Marnay, J
Arsène, D
Lechevrel, M
机构
[1] Univ Caen, Grp Reg Etud Canc, Expt Cancerol Lab, F-14076 Caen 05, France
[2] Ctr Francois Baclesse, Anat Pathol Lab, F-14076 Caen, France
[3] CHU Cote Nacre, Dept Hepatogastroenterol, F-14033 Caen, France
关键词
D O I
10.1093/mutage/18.3.299
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We investigated TP53 mutation patterns in cancers of the esophagus and cardia of patients coming from Lower Normandy, a region situated in the highest incidence area in Europe. To screen tumor samples, we first used denaturing gradient gel electrophoresis (DGGE), a well-characterized technique which constituted our reference method. Then the results were compared with those obtained by denaturing high performance liquid chromatography (DHPLC), a recent and automatic screening technology. Analysis of the TP53 mutations profile showed that the detected alterations were mainly point mutations. Ninety-seven percent (33/34) of esophageal squamous cell carcinoma samples presented at least one mutation or polymorphism. The proportion of somatic, non-silent and sequence-confirmed mutations was 76% (26/34). The most common substitutions were G-->A transitions, which could be related to nitrosamines, acetaldehyde or factors prone to producing mucosal irritation, like hot beverages. G-->T transversions, which were also frequently detected, could originate from benzo[a]pyrene in tobacco smoke. A-->T transversions were not revealed in our series, which constitutes a discordance with mutational spectra already performed in north-western France. Concerning adenocarcinoma of the esophagus and cardia, the alteration frequency was 69% (11/16), with a majority of G-->A transitions at CpG dinucleotides. They are probably related to endogenous process mediated by inflammatory diseases like gastro-esophageal reflux and Barrett's esophagus. The main advantage provided by DHPLC was its ease of application. However, the optimization steps turned out to be quite critical, especially for sequences with high melting temperatures embedded in lower melting temperature fragments. Considering only the common sequences analyzed by the two techniques, four of the 46 positive samples detected by DGGE were not revealed by DHPLC. This result stresses the limited sensitivity of DHPLC compared with DGGE under the conditions described in this study.
引用
收藏
页码:299 / 306
页数:8
相关论文
共 47 条
[1]   Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression [J].
Ambs, S ;
Hussain, SP ;
Harris, CC .
FASEB JOURNAL, 1997, 11 (06) :443-448
[2]  
AUDREZET MP, 1993, CANCER RES, V53, P5745
[3]  
Biramijamal F, 2001, CANCER RES, V61, P3119
[4]   Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries [J].
Botterweck, AAM ;
Schouten, LJ ;
Volovics, A ;
Dorant, E ;
van den Brandt, PA .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2000, 29 (04) :645-654
[5]   Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers [J].
Denissenko, MF ;
Pao, A ;
Pfeifer, GP ;
Tang, MS .
ONCOGENE, 1998, 16 (10) :1241-1247
[6]   New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology [J].
Dolan, K ;
Sutton, R ;
Walker, SJ ;
Morris, AI ;
Campbell, F ;
Williams, EMI .
BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) :834-842
[7]  
Fléjou JF, 1999, J CLIN PATHOL-MOL PA, V52, P263
[8]   Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia [J].
Gleeson, CM ;
Sloan, JM ;
McManus, DT ;
Maxwell, P ;
Arthur, K ;
McGuigan, JA ;
Ritchie, AJ ;
Russell, SEH .
BRITISH JOURNAL OF CANCER, 1998, 77 (02) :277-286
[9]   Mutation analysis of p53 in ovarian rumors by DHPLC [J].
Gross, E ;
Kiechle, M ;
Arnold, N .
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 2001, 47 (1-2) :73-81
[10]  
HAMELIN R, 1993, ONCOGENE, V8, P2213